RedHill Biopharma (RDHL) has released an update.
RedHill Biopharma Ltd. has reported a significant reduction in mortality rates among moderate to severe COVID-19 pneumonia patients treated with their drug opaganib. The published post-hoc analysis from a phase 2/3 study shows a 62% decrease in death rates and a 21% improvement in recovery times. These results indicate that opaganib, an orally administered treatment with a favorable safety profile, could be a promising new therapy for hospitalized COVID-19 patients.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
